{"id":"W2980937306","doi":"10.1038/s41375-019-0602-x","title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","year":2019,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":463,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; TG Therapeutics; Astellas Pharma; BeiGene; Gilead Sciences; GlaxoSmithKline; Pharmacyclics; Genentech; Sunesis; Teva Pharmaceutical Industries; Celgene; AstraZeneca; Bristol-Myers Squibb","keywords":"Ibrutinib; Chlorambucil; Internal medicine; Neutropenia; Medicine; Chronic lymphocytic leukemia; IGHV@; Adverse effect; Hematology; Oncology; Gastroenterology; Leukemia; Chemotherapy; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002193253,0.0002091837,0.0005847287,0.00006154819,0.00005246209,0.00001113099,0.0001870846,0.00009138399,0.00008288454],"category_scores_gemma":[0.0001721415,0.0001284107,0.0001005842,0.0001788886,0.0001491461,0.00004853412,0.00009929555,0.0001155685,0.000009113764],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003739966,"about_ca_system_score_gemma":0.001444819,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001433717,"about_ca_topic_score_gemma":0.0003807659,"domain_scores_codex":[0.9982374,0.0000579463,0.0004463586,0.0004089837,0.0005398833,0.0003094834],"domain_scores_gemma":[0.9976087,0.001106641,0.0001891281,0.0007978646,0.0001754296,0.0001222436],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.05682265,0.004078681,0.8651747,0.0003437853,0.001445297,0.00006136527,0.005701291,0.00005485595,0.0003283714,0.00001816805,0.0004389305,0.06553192],"study_design_scores_gemma":[0.3759435,0.01414117,0.60457,0.0004189527,0.0005201485,0.000004937047,0.000257434,0.001004804,0.001452912,0.000007923651,0.001504555,0.0001737022],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9951472,0.0002307342,0.00002207595,0.00009081201,0.0000965056,0.00407856,0.0002379442,0.00001910553,0.0000770847],"genre_scores_gemma":[0.9988234,0.00009644711,0.0001266333,0.00004111513,0.0000708034,0.00006388657,0.000217699,0.00004358712,0.0005164346],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3191208,"threshold_uncertainty_score":0.9779882,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0243989745233313,"score_gpt":0.3168264164823156,"score_spread":0.2924274419589843,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}